Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer’s disease, according to the federal clinical trials database.
About eight months ago, Asceneuron disclosed a $100 million Series C to advance its O-GlcNAcase (OGA) inhibitor ASN51 into a Phase 2 study. The biotech ran the trial, which was expected to take two years, for less than a month before terminating it, according to the trial’s entry in the database.....
Shortly after Asceneuron’s fundraise in July, Eli Lilly — its main competitor — said a drug in the same class failed a Phase 2 test. Then, last month, Biogen scrapped an early-stage drug in the same class.
All three companies were trying to develop OGA inhibitors, which they believed would slow or curb the buildup of tau in patients with Alzheimer’s....
NUZ Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)